Study of Epigenetic and Inflammatory Markers of Accelerated Biological Ageing in the Follow-up of Patients With Hodgkin's Lymphoma in Complete Remission for at Least 2 Years
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 200
- 试验地点
- 1
- 主要终点
- evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)
研究概览
简要总结
Study design: It is a monocentric and exploratory study, experimental on human tissues in vitro which involves the analysis of peripheral blood in patients with Hodgkin's lymphomas with the following characteristics:
- in complete remission for at least two years after first-line therapy with stage IIb, III or IV at onset (Ann Arbor classification).
- newly diagnosed (stage IIb, III or IV, Ann Arbor Classification).
详细描述
The study aims to evaluate patients with hodgkin lymphoma in complete remission for at least 2 years and newly diagnosed (stage II b, stage III or stage IV) as they are currently characterised by a long life expectancy during which there is an increased and early incidence of non-neoplastic systemic complications as well as, of course, manifestations of secondary malignancies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Health Services Research
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •hodgkin lymphoma stage II b, III or IV at onset in remission for at least two years after the first line of therapy for lymphoma
- •Newly diagnosed histologically confirmed stage II b, III or IV patients who require first-line therapy
- •Patients of both sexes aged ≥ 18 years at enrollment
- •Signature of informed consent
排除标准
- •Concomitant second neoplasm
研究组 & 干预措施
hodgkin lymphoma patients in complete remission for at least two years and newly diagnosed
in vitro human tissue testing of peripheral blood in hodgkin lymphoma patients in complete remission for at least two years after first-line therapy with stage II b, III or IV
干预措施: peripheral blood sampling (Other)
结局指标
主要结局
evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)
时间窗: through study completion, an average of 2 year
Determine the biological age of patients
DNA methylation (methylation rate)
时间窗: through study completion, an average of 2 year
Determine the biological age of patients
次要结局
- evaluation of senescence markers (CD57, KLRG1,CD62L, CD45RA)(through study completion, an average of 2 year)
- DNA methylation (methylation rate)(through study completion, an average of 2 year)